Researchers identify target for cancer drugs
...mTOR has been widely studied as the target for the immunosuppressant drug rapamycin (in fact, mTOR is an acronym for "mammalian target of rapamycin"). In July of 2004, Dos Sarbassov, a scientist in Sabatini's lab, discovered a new protein that mTOR interacts with called rictor, but he wasn't yet sure of what these two...Double triumph in stem cell quest
...ected by patients' immune systems unless they take immunosuppressant drugs. This is why many stem cell researchers are trying to create ESCs that are identical to people's own cells. Last year Woo Suk Hwang of Seoul National University claimed to have created an ESC line from a cloned human embryo for the first time....Portable cocaine sensor developed at UC Santa Barbara
...drugs may be profound. A drug like cyclosporin, an immunosuppressant that has revolutionized the field of organ transplants, must be carefully monitored in a patient's blood to regulate the dosage. The test to check the ratio of a therapeutic dose versus a lethal dose is a process that takes six hours. With the new se...Genetic 'roadmap' charts links between drugs and human disease
...rber Cancer Institute, identified the FDA-approved immunosuppressant drug, sirolimus (also known as "rapamycin"), as a therapeutic candidate for overcoming drug resistance in a form of human leukemia. These findings, as well as those for gedunin, are described in Science and in separate Cancer Cell publications. "Al......ort the unique action of FTY720, or Fingolimod, an immunosuppressant drug that was already known to affect the functioning of the immune system by preventing the egress of white blood cells from the lymph nodes into the blood. The article was pre-published as a First Edition Paper in Blood, The Journal of the American...Better Drug for Heart Transplant
...during the first 12 months is a safe and effective immunosuppressant regimen for use in recipients of a first heart transplant." Researchers say further evaluation and follow-up are needed to determine the optimal dose. However, they say the findings of this study offer some optimism that everolimus is a promising ag...Stent Effective In Keeping Arteries Open
... The experimental stent, a mesh tube, releases the immunosuppressant drug everolimus. The drug acts by inhibiting cell reproduction and reducing cell growth in vessel walls. Unlike other similar drug-eluting stents, the one used in this study is made with a biodegradable polymer researchers believe will reduce and min...Immunosuppressive drug shows promise in treatment of eye disorder
It is a routine practice to prescribe drugs called immunosuppressant to transplant patients to prevent the transplanted organs from being rejected. The medical community has only been interested in worrying about the problems caused due to immunosuppression. Looking at the other side of the coin, there seems to be ben...Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines
...nimise chances of rejection and eliminate need for immunosuppressant drugs. Unlike the one to one donor – patient liver, cardiac and renal transplants being performed currently, a single stem cell line could be exploited to benefit multiple recipients. Despite potential advantages of stem cell therapy, much progress......ow the researchers are working on better and safer immunosuppressant therapies to establish safer treatment options to people. The works of the researchers will be published in the medical journal, Nature Medicine. If this research works then it would be possible to start clinical trials in humans in the next three ...Early Results of the CellCept Spare the Nephron Study Examine Kidney Function
...on renal function. About CellCept CellCept is an immunosuppressant or anti-rejection drug approvedfor use in combinat...effusion, tremor and insomnia. Patients receiving immunosuppressant regimens are at increasedrisk of developing lymphomas and other malignancies, particularlyof the ski...Isotechnika Announces Interim Three Month Data from Phase 2b Kidney Transplant Trial
...chnika looks to become theleader in development of immunosuppressant therapies. Isotechnika'slead drug, ISA247, has successfully completed a Phase 3 Canadiantrial for the treatment of moderate to severe psoriasis. ISA247 iscurrently being investigated in a combined Phase 3European/Canadian psoriasis trial and a Phase ......chnika looks to become theleader in development of immunosuppressant therapies. Isotechnika's lead drug, ISA247, has successfully completed aPhase 3 Canadian trial for the treatment of moderate to severepsoriasis. ISA247 is currently being investigated in a combinedPhase 3 European/Canadian psoriasis trial and ......h intravenous steroidsand after induction with the immunosuppressant mitoxantrone; itscompatibility with other compounds may make it unique among thedisease modifying class of drugs and a treatment of interest forthe future study of combination therapies for MS," Metz added. About the Study This double-blind, random...